Houston Medical Robotics Inc.
Aiming to standardize and automate central venous access
This article was originally published in Start Up
Executive Summary
More than five million central venous catheter lines are placed in the US each year, but the high-volume, invasive procedure has a troubling 2% to 26% procedural error rate, and can cause serious and expensive complications. Houston Medical Robotics Inc. has developed the Euclid Tier 1 Mini Access image-guided medical robotics vascular access platform to standardize, automate, and increase the safety of this critical procedure.
You may also be interested in...
J&J And Sanofi Team Up On Phase III E. Coli Vaccine
Sanofi will pay $175m up front for rights to commercialize J&J’s potential first-in-class vaccine against E. coli. The two companies will share profits.
Minute Insight: Medtronic May Sell Respiratory And Monitoring Units To Private Equity
Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.
Humic Acid Nasal Sprays Recalled During Potential For Sales Boost Due To Phenylephrine Doubts
Biomic Sciences recalls all lots of ION* Sinus Support and ION* Biome Sinus after FDE testing found microbial contamination causing reasonable probability of life-threatening adverse events for patients or people who recently underwent nasal or sinus surgery.